Cftr Trikafta denied as not FDA-approved for this use by CVS Caremark?

Trikafta covered for FDA-labeled mutations + CF center attestation. Symdeko/Orkambi non-preferred when Trikafta-eligible.

CFF 2023 Modulator Recommendations + CFTR2 database for non-F508del responsive variants. April 2023 FDA expansion to age 2-5 (VX20-445-111). Step-therapy through inferior modulator contradicts CFF first-line Trikafta recommendation.

## Why CVS Caremark May Issue a "Not FDA-Approved" Denial for Trikafta

Trikafta (elexacaftor/tezacaftor/ivacaftor) holds FDA approval for cystic fibrosis patients who carry at least one specific class of CFTR mutation. A "not FDA-approved" denial from CVS Caremark almost always means the plan's system could not confirm that your documented mutation profile falls within the approved indication — not that the drug itself lacks FDA clearance. This is a technical error that is routinely overturned on appeal when the right records are supplied.

## Why It Is Appealable

A denial premised on a regulatory status that is factually incorrect is among the strongest grounds for appeal. Because the FDA approval is a matter of public record, your prescriber can cite the current FDA-approved prescribing label directly and cross-reference your confirmed CFTR genotype from a certified laboratory report.

## Federal Appeal Framework

• Internal appeal (Level 1): File within the timeframe stated in your Explanation of Benefits (EOB). CVS Caremark must issue a decision within the regulatory deadline — typically 30 days for non-urgent requests or 72 hours for expedited/urgent cases.
• External review (ACA §2719 / ERISA §503): If the internal appeal is denied, you have the right to an Independent Review Organization (IRO) review under ACA §2719. For ERISA-governed employer plans, §503 guarantees a full-and-fair review. You generally have approximately 4 months from the denial notice to request external review. An expedited track is available when your treating physician certifies that the standard timeline would seriously jeopardize your health.

## Documentation to Gather

1. Genetic testing report — a certified laboratory report confirming your CFTR mutation(s) by name, issued by a CLIA-certified lab. 2. Current FDA prescribing label — download directly from FDA.gov; highlight the approved mutation list and confirm your mutation appears. 3. Diagnosis confirmation — pulmonologist or CF specialist records documenting the cystic fibrosis diagnosis. 4. Prescriber medical-necessity letter — your CF specialist should state that your genotype falls within the FDA-approved indication and explain why Trikafta is medically necessary for your specific case. 5. EOB and denial letter — include the exact denial language so the reviewer can see the stated basis.

## Criteria-Mapping Structure

Create a simple table in your appeal letter with two columns:

| Plan/FDA Requirement | Chart Evidence Meeting It | |---|---| | FDA-approved mutation type (per current label) | Lab report dated [date], confirming mutation [as named in your record] | | Confirmed CF diagnosis | Clinic note from [provider], dated [date] | | Prescriber determination of appropriateness | Medical-necessity letter attached |

Fill every row with the specific document and date from your own records. This structure makes it straightforward for a reviewer to verify compliance without ambiguity.

## Next Step

Obtain the current FDA-approved prescribing label from FDA.gov and compare the approved mutation list against your certified lab report before submitting. If there is any possibility of a coding or transcription error in how the plan received your mutation data, ask your prescriber's office to resubmit the prior authorization with the corrected mutation nomenclature simultaneously.